Navigation Links
Anthera Announces Last Patient Enrolled in PEARL-SC Study
Date:10/25/2011

HAYWARD, Calif., Oct. 25, 2011 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has completed enrollment in the Phase 2b PEARL-SC study.  PEARL-SC (A randomized, double-blind Phase 2b study to evaluate the efficacy, safety, and tolerability of blisibimod administration in subjects with systemic lupus erythematosus) is examining the therapeutic benefit of weekly and monthly subcutaneous injections of blisibimod in patients with active and antibody positive systemic lupus erythematosus (SLE).  The targeted number of five hundred and forty (540) patients has been randomized in 11 countries and 72 clinical sites worldwide.

Also, as part of the Company's efforts to improve treatment options for patients with SLE, the Company submitted a protocol amendment to the FDA for the PEARL-SC clinical study that proposes a modification in the primary efficacy SLE response index to require a larger decrease in the SELENA-SLEDAI* clinical assessment score.  The proposed primary endpoint will require patients to demonstrate a greater than or equal to five (>5) point reduction in the SELENA-SLEDAI, a well-recognized clinical assessment of lupus activity.  The remainder of the responder index will remain unchanged with no new BILAG A or two new BILAG B organ domain flares, and less than a 0.3 (<0.3) increase on a three point scale in Physician's Global Assessment.

"As we move forward with the development of blisibimod, we are incorporating feedback from industry experts, physicians, and key opinion leaders regarding the potential for blisibimod to provide incremental benefits to patients with systemic lupus erythematosus compared to currently available therapies and other advanced stage clinical treatments," said Colin Hislop
'/>"/>

SOURCE Anthera Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Anthera Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application Covering A-002 Plus Statin Compositions
2. Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update
3. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
4. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
5. Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update
6. Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
7. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
8. Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance
9. Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors
10. Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Antheras Investigational Novel Peptibody Agent
11. Anthera Announces Update Call Regarding Vial Problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... N.C. , May 22, 2013 STEPh, ... to announce the launch of their web site ( ... [STEPh Reports].  About STEPh Reports ... in development.  Each STEPh Report assesses ... trials data, projected launch year, company, and specific key ...
(Date:5/22/2013)... , May 22, 2013 MEDIFIRST SOLUTIONS, INC. ... update shareholders about some recent company developments. As Medifirst ... avenues of communication with shareholders. Integrating social media into ... Facebook page and will post updates on Twitter.  The ... is #medifirstusa. Says CEO ...
(Date:5/22/2013)... 22, 2013 Ranbaxy Laboratories Limited (hereafter, ... (hereafter, Daiichi Sankyo), announced on May 22 the ... to address past conduct under prior management ... Daiichi Sankyo continues to support Ranbaxy in its ... the past which led to the investigations by ...
Breaking Medicine Technology:Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site 2Medifirst Solutions, Inc. Announces Update To Shareholders 2
(Date:5/22/2013)... The health care crisis in the United States is ... percent of all adults are without health insurance. Further, ... U.S. are related to medical bills. The high price ... patients cannot afford to take their prescriptions as directed by ... That's why MedicationDiscountCard.com is offering savings of up to seventy-five ...
(Date:5/22/2013)... 2013 NBA Draft tickets go on sale to the ... The 2013 NBA Draft will be held at the new Barclays ... Nets. The Barclays Center has already become a mecca for ... Paul McCartney and Beyonce have already booked sold out concerts at ... perform at this state-of-the-art venue. Disney on Ice will also ...
(Date:5/22/2013)... May 22, 2013 Abadir Associates, a ... treatments for optimal results, is offering a new technique ... neck. The practice has successfully treated multiple patients ... “Basically, this approach is for women who want to ... dermatologist Dr. Michelle Abadir of Abadir Associates. ...
(Date:5/22/2013)... - May 22 2013: New research shows that ... in specific regions of the brain that are ... planning actions and in motivation. Dr. Alain ... these decision-making brain regions could underlie addiction. These ... Meeting, the annual meeting of the Canadian Association ...
(Date:5/22/2013)... By Dennis Thompson HealthDay Reporter , , TUESDAY, ... Americans isn,t improving much, with about six in 10 ... in unhealthy behaviors like smoking, heavy drinking or not ... Tuesday by the U.S. Centers for Disease Control and ... of the lifestyle choices that have led to soaring ...
Breaking Medicine News(10 mins):Health News:Lyrica Discount Cards Now Available From MedicationDiscountCard.com 2Health News:2013 NBA Draft Tickets: Cheap Concert Tickets Announces that Official Onsales for the 2013 NBA Draft Begin at 10:00 am Local Time on Wednesday, May 22, 2013 2Health News:Westchester Dermatologist Abadir Associates Offers New Neck Lift Surgery Alternative 2Health News:Addiction as a disorder of decision-making 2Health News:Americans Still Making Unhealthy Choices: CDC 2Health News:Americans Still Making Unhealthy Choices: CDC 3
... by the U.S. Food and Drug Administration (FDA) for a new ... moderate to severe postmenopausal dyspareunia (painful sexual intercourse) announced Wyeth Pharmaceuticals, ... ... Pa. (Business Wire EON) November 13, 2008 -- "This approval ...
... of nest eggs, homes or jobs, their young children ... Michele C. Thorne, Ph.D., assistant professor of clinical psychology ... director of the Consult Liaison Service at Riley Hospital ... newborn babies pick up on the emotional tones of ...
... Inc.,(Nasdaq: SUPG ), a pharmaceutical company dedicated ... today announced that James S.,Manuso, Ph.D., President and ... Lazard Capital Markets Fifth Annual Healthcare Conference on,Tuesday, ... New York, New York., SuperGen,s presentation at ...
... Dowden Health Media,s,beginnings were reflected in an article written ... the Dowden Dispatch an employee newsletter,which published in the ... Mark Dowden, one of the founders of Dowden Health ... 1988, as he stood,in his parents, kitchen chatting with ...
... repair providers join forces to provide superior customer ... Inc., Multi Vendor,Service announced today that it will ... most respected leaders in the ultrasound transducer repair,industry., ... relationship brings together two of the most reputable,high-quality ...
... assassins, many diseases seem to know exactly what types ... of cells, diseases will inexplicably spare a seemingly identical ... depends largely on the kinds and amounts of proteins ... of molecular biology. For this reason, scientists have struggled ...
Cached Medicine News:Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia &#8211; Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 2Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia &#8211; Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 3Health News: FDA Approves Low-dose Regimen of PREMARIN Vaginal Cream to Treat Moderate to Severe Postmenopausal Dyspareunia &#8211; Painful Sexual Intercourse : Agency Grants New Indication for Bothersome Vaginal Symptom Associated with Menopause 4Health News:Helping children and teens deal with stress in an uncertain time 2Health News:Dowden Health Media: 20 Years and Growing 2Health News:MEDRAD Multi Vendor Service Forms Alliance with Wetsco 2Health News:MEDRAD Multi Vendor Service Forms Alliance with Wetsco 3Health News:Breakthrough in cell-type analysis offers new ways to study development and disease 2Health News:Breakthrough in cell-type analysis offers new ways to study development and disease 3Health News:Breakthrough in cell-type analysis offers new ways to study development and disease 4
Inquire...
Sealing Mat for 384-well, Square Well Plates Available Sterile...
96-well Silicone Expansion Mat, Bulk...
Microseal 'M' mats, seals 96-well plates, reusable, pkg of 10...
Medicine Products: